Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Didier Meulendijks

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|May 15, 2016
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasmaBart A W Jacobs, Hilde Rosing, Niels de Vries, et al.
Clinical Pharmacology and Therapeutics|November 13, 2023
A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer RegimensJonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, et al.
Neuropharmacology|August 3, 2011
Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized ratsHendrikus Hendriksen, Didier Meulendijks, Tessa N Douma, et al.
Pharmacogenomics|August 13, 2015
Translating DPYD genotype into DPD phenotype: using the DPYD gene activity scoreLinda M Henricks, Carin A T C Lunenburg, Didier Meulendijks, et al.
International Journal of Cancer|November 29, 2018
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysisLinda M Henricks, Lisanne N van Merendonk, Didier Meulendijks, et al.
International Journal of Cancer|July 21, 2015
Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R alleleDidier Meulendijks, Bart A W Jacobs, Abidin Aliev, et al.
British Journal of Clinical Pharmacology|January 25, 2021
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicitySeid Hamzic, Dominic Schärer, Steven M Offer, et al.
Future Oncology (London, England)|April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2016
Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical careDidier Meulendijks, J G Coen van Hasselt, Alwin D R Huitema, et al.
International Journal of Cancer|January 26, 2016
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicityDidier Meulendijks, Linda M Henricks, Ursula Amstutz, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Journal of Pharmaceutical and Biomedical Analysis|May 15, 2016
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasmaBart A W Jacobs, Hilde Rosing, Niels de Vries, et al.
Clinical Pharmacology and Therapeutics|November 13, 2023
A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer RegimensJonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, et al.
Neuropharmacology|August 3, 2011
Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized ratsHendrikus Hendriksen, Didier Meulendijks, Tessa N Douma, et al.
Pharmacogenomics|August 13, 2015
Translating DPYD genotype into DPD phenotype: using the DPYD gene activity scoreLinda M Henricks, Carin A T C Lunenburg, Didier Meulendijks, et al.
International Journal of Cancer|November 29, 2018
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysisLinda M Henricks, Lisanne N van Merendonk, Didier Meulendijks, et al.
International Journal of Cancer|July 21, 2015
Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R alleleDidier Meulendijks, Bart A W Jacobs, Abidin Aliev, et al.
British Journal of Clinical Pharmacology|January 25, 2021
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicitySeid Hamzic, Dominic Schärer, Steven M Offer, et al.
Future Oncology (London, England)|April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2016
Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical careDidier Meulendijks, J G Coen van Hasselt, Alwin D R Huitema, et al.
International Journal of Cancer|January 26, 2016
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicityDidier Meulendijks, Linda M Henricks, Ursula Amstutz, et al.
Pageof 5